Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice.

Nakagawa, Tomoo; Kobayashi, Taku; Nishikawa, Kiyohiro; Yamada, Fumika; Asai, Satoshi; Sameshima, Yukinori; Suzuki, Yasuo; Watanabe, Mamoru; Hibi, Toshifumi

Nakagawa, Tomoo; Kobayashi, Taku; Nishikawa, Kiyohiro; Yamada, Fumika; Asai, Satoshi; Sameshima, Yukinori; Suzuki, Yasuo; Watanabe, Mamoru; Hibi, Toshifumi.

Afiliação

Nakagawa T; Department of Gastroenterology, Chiba University Hospital, Chiba, Japan.
Kobayashi T; Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
Nishikawa K; Quality & Pharmacovigilance Division, Pharmaceuticals Group, Nippon Kayaku Co., Ltd., Tokyo, Japan.
Yamada F; Quality & Pharmacovigilance Division, Pharmaceuticals Group, Nippon Kayaku Co., Ltd., Tokyo, Japan.
Asai S; Department of Gastroenterology, Tane General Hospital, Osaka, Japan.
Sameshima Y; Department of Internal Medicine, Sameshima Hospital, Kagoshima, Japan.
Suzuki Y; Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan.
Watanabe M; Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
Hibi T; Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.

Intest Res ; 17(4): 504-515, 2019 Oct.

Article em En | MEDLINE | ID: mdl-31422647

Palavras-chave

Biosimilar; CT-P13; Inflammatory bowel disease; Infliximab; Post-marketing surveillance

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Intest Res Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google